SFM
LOGC

Sphera Funds Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Sphera Funds Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,042
Closed -$110K – 137
2021
Q3 		$110K Buy
+24,042
New +$106K 0.01% 115
2019
Q2 		– Sell
-417,625
Closed -$4.13M – 119
2019
Q1 		$4.13M Hold
417,625
– – 0.38% 64
2018
Q4 		$4.34M Buy
+417,625
New +$5.04M 0.49% 46

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

Sphera Funds Management's LOGC Position: Q4 2021 in Review

Sphera Funds Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2021, closing a stake of 24,042 shares — an estimated $110K sold.

Sphera Funds Management first reported a position in LOGC in Q4 2018 and held it in 3 quarters. The position peaked at $4.34M in Q4 2018. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

  • Sphera Funds Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Sphera Funds Management sold 24,042 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $110K.
  • Sphera Funds Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 3 quarters.
  • Sphera Funds Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $4.34M in Q4 2018.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Sphera Funds Management's 13F filing for Q4 2021, filed 14 Feb 2022.